Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 36
- Registration Number
- NCT02197442
- Locations
- 🇮🇳
Lambda Therapeutic Research Ltd.,, Ahmedabad, Gujarat, India
Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 40
- Registration Number
- NCT02197494
- Locations
- 🇮🇳
Lambda Therapeutic Research Ltd., Navi Mumbai, Maharashtra, India
MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 426
- Registration Number
- NCT02177396
Intermittent Hypoxia 2: Cardiovascular and Metabolism
- Conditions
- Interventions
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 12
- Registration Number
- NCT02058823
- Locations
- 🇫🇷
Laboratoire EFCR - Functional Cardio-respiratory Exploration Laboratory, La Tronche, Isère, France
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4822
- Registration Number
- NCT01920711
- Locations
- 🇬🇧
Novartis Investigative Site, Wrexham, United Kingdom
Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 480
- Registration Number
- NCT01917149
- Locations
- 🇨🇳
Xijing Hospital, Department of Cardiology, Xi'an, China
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 211
- Registration Number
- NCT01912534
- Locations
- 🇨🇦
Toronto Sick Kids, Toronto, Ontario, Canada
🇺🇸Stanford University, Stanford, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT01878201
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide
- Conditions
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2013-01-15
- Lead Sponsor
- Damanhour University
- Target Recruit Count
- 24
- Registration Number
- NCT01767259
- Locations
- 🇪🇬
Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)
- Conditions
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- Damanhour University
- Target Recruit Count
- 24
- Registration Number
- NCT01767298
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.